Literature DB >> 9703779

Prognostic factors in breast cancer: a brief review.

M Fernö1.   

Abstract

Prognostic factors, e.g. metastatic disease, lymph node status, tumour size, histologic grade, estrogen and progesterone receptors, and markers of proliferation are used to predict the clinical course of breast cancer at the time of primary treatment. Patients with a poor prognosis are offered adjuvant therapy. For the choice of adjuvant therapy (endocrine or cytotoxic) treatment predictive factors, e.g. estrogen and progesterone receptor; are useful. Putative new prognostic factors (e.g. oncogenes, tumour suppressor genes, and invasive factors) should be evaluated together with the clinical established factors in multivariate analyses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9703779

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties.

Authors:  M J Page; B Amess; R R Townsend; R Parekh; A Herath; L Brusten; M J Zvelebil; R C Stein; M D Waterfield; S C Davies; M J O'Hare
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

Review 2.  [Contrast-enhanced mammography].

Authors:  Eva M Fallenberg
Journal:  Radiologe       Date:  2021-01-18       Impact factor: 0.635

3.  Genetic variants of EGFR (142285G>A) and ESR1 (2014G>A) gene polymorphisms and risk of breast cancer.

Authors:  Ranbir Chander Sobti; Marjan Askari; Mohsen Nikbakht; Neha Singh; Suresh C Sharma; Abayneh Munshea Abitew
Journal:  Mol Cell Biochem       Date:  2012-07-19       Impact factor: 3.396

4.  Breast cancer local recurrence: risk factors and prognostic relevance of early time to recurrence.

Authors:  A Neri; D Marrelli; S Rossi; A De Stefano; F Mariani; G De Marco; S Caruso; G Corso; T Cioppa; E Pinto; F Roviello
Journal:  World J Surg       Date:  2007-01       Impact factor: 3.352

5.  Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer.

Authors:  Sebastian F Schoppmann; Guenther Bayer; Klaus Aumayr; Susanne Taucher; Silvana Geleff; Margaretha Rudas; Ernst Kubista; Hubert Hausmaninger; Hellmut Samonigg; Michael Gnant; Raimund Jakesz; Reinhard Horvat
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

Review 6.  The benefits and limitations of sentinel lymph node biopsy.

Authors:  Farin Amersi; Nora M Hansen
Journal:  Curr Treat Options Oncol       Date:  2006-03

7.  Histamine, mast cells and tumour cell proliferation in breast cancer: does preoperative cimetidine administration have an effect?

Authors:  P F Bowrey; J King; C Magarey; P Schwartz; P Marr; E Bolton; D L Morris
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.